Company
Every investor coverage indicates participated in a round Alfred Health raised.
Companies Alfred Health acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Alfred Health. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Weekly roundup detailing new capital for Australian startups Diraq, BrainFish, RecycleSmart, Cohabit and Five Faces, alongside Alumly's undisclosed multimillion-dollar backing from UK investor Mauve Group.
Also Startup Daily
Five Faces, a Queensland health software company, has brought in its first outside capital: a Series A round with Utiliti Group leading and grant support from the Female Founders Co-Investment Fund.
Aravax has finished enrolling 95 young patients in its Phase 2 peanut-allergy immunotherapy trial across US and Australian sites, with results expected in the first half of 2026.
Breakthrough Victoria announces a $12 million investment in Aravax, part of a $66 million Series B, advancing the biotech's peanut allergy immunotherapy into phase two trials in Australia and the United States.
Also Brandon Capital portfolio·Brandon BioCatalyst portfolio·@AuManufacturing·Business News Australia·@AuManufacturing·Forbes Australia·Startup News (WA)
Aravax has begun its Series B with a US$20 million investment from Brandon Capital and Tenmile, funding Phase 2 trials of its peanut allergy immunotherapy PVX108 while it seeks further capital.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Forbes Australia·Techboard·Business News Australia